

Drug-Induced Hepatotoxicity

Contributors

S. Anuras, M.Z. Badr, A.S. Basile, S.A. Belinsky, L.M. Blendis
R.G. Cameron, J.G. Conway, F.A. de la Iglesia, M.U. Dianzani
E. Farber, G. Feuer, R.J. Fingerote, P.E. Ganey, A.K. Ghoshal
K.G. Ishak, Y. Israel, E.A. Jones, K. Kitani, C.D. Klaassen
J.S. Leeder, G.A. Levy, I.R. Mackay, D.K. Monteith, A.B. Okey
B.K. Park, M. Pirmohamed, W.F. Pool, E.A. Roberts, E. Rubin
R.W. Sallie, D.C. Snover, R.G. Thurman, F. Trevisani, D.H. Van Thiel
R.R. Varma, R.M. Walker, J.B. Watkins III, P.G. Welling
T.F. Woolf, H.J. Zimmerman, M.J. Zuckerman

Editors

R.G. Cameron, G. Feuer, and F.A. de la Iglesia

With a Foreword by M. James Phillips



Springer

Contents

CHAPTER 1

Orientation in Liver Toxicity by Drugs

E. FARBER. With 1 Figure	1
A. Introduction	1
B. Agents and Processes	1
C. Responses to Injury as Multitier or Multigrid Patterns	2
I. Quantitative Versus Qualitative Changes	3
II. Patterns of Liver Toxicity	4
1. Tier One: Patterns of Interactions of Agents with Liver	4
2. Tier Two: Patterns of Biological Responses to Cell Injury	8
3. Tier Three: Cellular and Intracellular Responses	10
4. Tier Four: Cellular and Tissue Physiology	19
D. Conclusion	21
References	21

CHAPTER 2

Clinical Studies and Role of Necrosis in Hepatotoxicity

R.G. CAMERON and L.M. BLENDIS. With 7 Figures	25
A. Zonal Necrosis as a Response to Acetaminophen	25
I. Zonality: Specific Hepatocytes Die as a Group	25
II. Ethanol Plus Acetaminophen: Extension of Zone of Necrosis	28
III. Constitutive Bases of Zonal Responses	30
1. Perivenous Localization of Acetaminophen-Metabolizing enzyme CYP 2E1	32
IV. Zonal Hepatocellular Necrosis: Historical Perspective	33
B. Regeneration in Response to Zonal Necrosis of Acetaminophen Overdose	33
I. Regeneration of Periportal and Mid-zonal Hepatocytes to Restore the Perivenous Zone	33

C. Clinical Implications of "Adaptive" Perivenous Necrosis	38
References	39

CHAPTER 3

Subcellular Biochemical and Pathological Correlates in Experimental Models of Hepatotoxicity

G. FEUER and F.A. DE LA IGLESIA. With 5 Figures	43
A. Introduction	43
B. Organization of the Liver Cell	44
C. Liver Cell Injury	45
D. Subcellular Organelle Pathology	46
I. Endoplasmic Reticulum	46
1. Membrane Structure	46
2. Cytochrome P450 System	48
3. Proliferation and Induction	48
4. Structure-Activity Relationships	50
5. Membrane-Bound Phospholipids	51
II. Golgi Apparatus	52
III. Intracellular Membrane Dynamics	54
IV. Mitochondria	55
V. Lysosomes	56
VI. Peroxisomes	57
E. Biochemical Pathology of Subcellular Changes	59
I. Cell Respiration	59
II. Protein Metabolism	60
III. Lipid Metabolism	61
IV. Bile Secretion	62
F. Latent Hepatotoxicity Models	63
G. Conclusions	64
References	65

CHAPTER 4

Molecular Biology of Hepatic Drug Reactions

R.W. SALLIE and E.A. JONES. With 6 Figures	75
A. Introduction	75
B. General Considerations	75
C. DNA Damage	77
I. Drugs and DNA Metabolism	77
II. DNA Replication and Repair Pathways	78
D. Inhibition of DNA Replication	79
I. Inhibition of DNA Polymerases	79
II. Inhibition of DNA Ligase	80

III. Chain Termination	81
IV. Inhibition of DNA Repair	81
V. Alterations in Purine/Pyrimidine Metabolism	83
VI. Alterations in DNA Processing Post Synthesis	83
E. Damage to RNA	84
F. Interference with Protein Synthesis	85
G. Apoptosis	86
H. Future Developments	92
I. Summary and Conclusions	93
References	94

CHAPTER 5

In Vitro Models of Liver Toxicity

R.G. THURMAN, P.E. GANEY, S.A. BELINSKY, J.G. CONWAY, and M.Z. BADR. With 4 Figures	99
A. Introduction	99
I. Metabolism of Foreign Compounds	
Can Cause Zone-Specific Hepatotoxicity	99
II. Advantages and Disadvantages of Whole Cell Models	100
B. Techniques Used to Study Zone-Specific Hepatotoxicity in the Isolated Perfused Liver	101
I. Metabolite Measurements in Tissue and Perfusate	103
II. Microlight Guides	104
III. Miniature Oxygen Electrodes	105
IV. Trypan Blue Exclusion	106
C. Applying In Vitro Models to the Study of Liver Toxicology	106
I. Monooxygenation in Periportal and Pericentral Zones of the Liver Lobule	106
II. Conjugation Reactions in Periportal and Pericentral Regions of the Liver Lobule	107
1. Sulfation	107
2. Glucuronidation	109
III. Oxygen as a Determinant of Zone-Specific Hepatotoxicity	111
D. Conclusions	113
References	113

CHAPTER 6

Cytochromes P450 and Liver Injury

J.S. LEEDER and A.B. OKEY. With 4 Figures	119
A. Drug Biotransformation, Cytochromes P450 and the Liver	119
I. Drug Biotransformation by the Liver	119
II. General Drug Biotransformation Processes	119

III. Phase I Reactions	120
IV. Introduction to the Cytochromes P450	120
B. Cytochromes P450 and Drug Biotransformation	121
I. Human Hepatic Cytochromes P450	121
II. Sources of Variability in P450 Expression and Activity	125
1. P450 Genetics and Polymorphisms	126
2. P450 Induction	127
3. P450 Inhibition	129
4. Liver Disease: Effects on Drug Biotransformation	130
II. Reaction Mechanism	130
III. Drug Biotransformation and Drug Toxicity	132
1. Cytochrome P450 and Bioactivation	132
2. Activation/Detoxification Balance	132
3. "Probe Drugs" for Determining P450 Activities in Humans In Vivo	134
C. Mechanisms of P450-Mediated Liver Injury	135
I. Reactive Metabolites	135
1. Noncovalent Interactions	136
2. Covalent Adduct Formation	137
II. P450s as Targets of Immune Effectors	138
D. Specific Drugs/P450s and Liver Injury	139
I. Acetaminophen	139
II. Halothane	141
III. Tienilic Acid	142
IV. Dihydralazine	143
V. Diclofenac	144
E. Conclusions	144
References	145

CHAPTER 7

Mechanisms of Drug-Induced Cholestasis

J.B. WATKINS III and C.D. KLAASSEN	155
A. Definition of Cholestasis	155
B. Mechanisms of Canalicular Bile Formation	156
I. Transport of Bile Acids	156
II. Transport of Inorganic Ions and Glutathione	157
III. Other Mechanisms	157
C. Mechanisms of Cholestasis	158
I. Alterations in Basolateral Membrane Function	158
II. Alterations in Canalicular Membrane Function	158
III. Alterations in Intracellular Events	159
1. Binding to Intracellular Proteins and Conjugation Enzymes	159
2. Cytoskeleton	159

IV. Permeability Changes in the Biliary Tree	160
1. Altered Permeability of the Junctional Complex	161
2. Altered Permeability of the Canalicular Membrane	161
3. Alterations in Membrane Proteins	162
4. Alterations in Membrane Composition and Function ...	164
D. Drugs and Other Chemicals Inducing Cholestasis	165
I. α -Naphthylisothiocyanate	165
II. Androgenic and Estrogenic Steroids	166
III. Bile Acids	168
IV. Chlorpromazine and Other Phenothiazines	169
V. Cyclosporine	170
VI. Miscellaneous Cholestatic Agents	170
References	171

CHAPTER 8

Fatty Liver and Drugs

M.U. DIANZANI. With 1 Figure	185
A. General Mechanisms for Fatty Liver	185
B. Drugs Provoking Fatty Liver	187
I. Drugs Provoking Fatty Liver by Increasing FFA Supply to the Liver	187
II. Drugs Provoking Fatty Liver by Intrahepatic Mechanisms	188
1. Drugs Increasing Intrahepatic FFA Synthesis	188
2. Drugs Provoking Fatty Liver by Decreasing Fatty Acid Oxidation	192
3. Drugs Blocking Lipoprotein Secretion	192
III. Drugs Decreasing Fat Infiltration in the Liver	200
References	202

CHAPTER 9

Choline Deficiency: An Important Model for the Study of Hepatotoxicity

A.K. GHOSHAL. With 2 Figures	211
A. Introduction	211
B. Hepatotoxicity by Dietary Manipulation – Not by Addition but by Depletion	212
C. Absence of Choline in an Otherwise Complete Diet – An Excellent Model for the Study of Liver Cell Death and Liver Cancer	213

I. Choline Deficiency Model and Cell Death	215
II. Choline Deficiency and Liver Cancer	216
D. Lipotrope Deficiency Versus Choline Deficiency	217
E. Step by Step Development of Liver Aberration	217
F. Hypothesis of Choline Deficiency Induced Hepatocarcinoma	218
G. Conclusions	218
References	218

CHAPTER 10

Immune Mechanisms and Liver Toxicity

I.R. MACKAY. With 3 Figures	221
A. Introduction and Overview of Drug-Mediated Hepatotoxicity	221
B. Functional Aspects of the Immune System	222
I. Immune Repertoire	222
II. Major Histocompatibility Complex	223
III. Afferent Limb of the Immune Response	224
IV. Efferent Limb of the Immune Response	225
V. Regulation and Dysregulation of Immune Responses	226
C. Genetic Determinants of Adverse Drug Reactions	227
D. Liver in Relation to Adverse Drug Reactions	228
I. Intrahepatic Metabolism of Drugs by Microsomal Enzymes	228
1. Cytochrome P450 Oxidases (CYP450)	228
2. UDP Glucuronosyl Transferases	228
3. Carboxyl Esterases	228
II. Intrahepatic Immune Processes	229
1. Initiation of Immune-Mediated Drug Reactions in the Liver	229
2. Regulatory and Dysregulation of Intrahepatic Immune Reactions	229
III. Infrequency of Hepatic Hypersensitivity Drug Reactions	230
IV. Immunopathology of Hepatic Hypersensitivity Drug Reactions	230
V. Drug-Altered Neoantigen – The Halothane Paradigm	232
1. Halothane Hepatitis	232
2. Immunological Investigations of Halothane Hepatitis	233
3. Detection of Antibodies to TFA Conjugates	233
VI. Native Liver Antigens – The Liver-Kidney Microsomal (LKM) System	234
1. Hepatitis with Anti-LKM-2	235
2. Identification of LKM as Cytochrome P450 Species	235

3. Antibodies to CYP 1A2 in Drug-Induced Hepatitis	236
4. Inhibition of Enzyme Function by Anti-LKM	237
5. Origins of Anti-LKM Reactivity	237
VII. Drug-Induced Hepatitis with Reactions to Autoantigens . . .	238
E. Experimental Models of Drug-Induced Immune-Mediated Disease	239
F. Laboratory Investigation of Immune-Mediated Hepatic Drug Reactions	240
I. General Laboratory Investigations	240
II. Drug-Specific Immunological Investigations	240
1. Detection of T-Cell-Mediated Reactions	241
III. Pharmacological Idiosyncrasy	242
References	242

CHAPTER 11

Hepatic Encephalopathy

A.S. BASILE	249
A. Introduction	249
I. Clinical Manifestations of Hepatic Encephalopathy	249
II. Neuropathological Changes in Hepatic Encephalopathy . . .	251
1. Anatomy	251
2. Electrophysiology	251
B. Involvement of Neurotoxins in the Pathogenesis of Hepatic Encephalopathy	252
I. Ammonia	253
1. Glial Interactions	253
2. Electrophysiological Changes	254
3. Changes in Oxidative Metabolism	256
4. Summary	256
II. Synergistic Neurotoxins	257
C. Neurotransmitter Involvement in the Pathogenesis of Hepatic Encephalopathy	258
I. γ -Aminobutyric Acid	258
1. Electrophysiology	258
2. Neurochemistry and Pharmacology	258
3. Behavior	260
4. Summary	260
II. Excitatory Amino Acids	261
III. Aromatic Amino Acids and Monoamine Neurotransmitters	263
D. Conclusions	265
References	265

CHAPTER 12

Liver Drug Reactions and Pregnancy

F. TREVISANI and D.H. VAN THIEL	273
A. The Liver in Normal Pregnancy	273
I. Liver Histology	273
II. Liver Perfusion and Function	274
B. Effects of Pregnancy on the Risk of Experiencing a Drug-Induced Hepatic Injury	276
I. Specific Pre-Marketing Risk/Benefit Evaluation of Drugs ..	276
II. Risk of Exposure to Hepatotoxic Drugs	276
III. Pharmacokinetics	278
1. Absorption	278
2. Distribution	278
3. Hemodynamics and Drug Clearance	279
4. Maternal-Placental-Fetal Unit	279
IV. Liver Vulnerability	280
C. Liver Drug Reactions Occurring During Pregnancy	282
I. Antibiotics	282
II. Antiemetics	283
III. Anesthetics and Analgesics	283
IV. Anticonvulsants	284
V. Other Agents	284
D. Clinical Presentation and Diagnostic Approach to Hepatic Injury in Pregnancy	285
E. Treatment	286
F. Prevention	287
References	288

CHAPTER 13

Pediatric Hepatic Drug Reactions

E.A. ROBERTS	293
A. Classification of Drug Hepatotoxicity	293
B. Specific Drugs Causing Hepatotoxicity in Children	294
I. Acetaminophen	294
II. Phenytoin	296
III. Valproic Acid	297
IV. Isoniazid	301
V. Halothane	302
VI. Carbamazepine	303
VII. Phenobarbital	304
VIII. Antineoplastic Drugs	304
IX. Pemoline	306

X. Sulfonamides	306
XI. Aspirin	307
XII. Propylthiouracil	307
XIII. Erythromycin	308
XIV. Methotrexate	308
XV. Estrogens: Oral Contraceptive Pill	310
XVI. Ketoconazole	310
XVII. Haloperidol	310
XVIII. Amiodarone	310
XIX. Nitrofurantoin	311
XX. Retinoids	311
XXI. Azathioprine	311
XXII. Cocaine	312
References	312

CHAPTER 14

Reye's Syndrome

R.R. VARMA	323
A. Introduction	323
B. Clinical Features	324
C. Laboratory Features	326
D. Diagnostic Criteria for Population Surveys	327
E. Liver Morphology	328
F. Brain Morphology	328
G. Liver Histology and Electron Microscopy in Reye's Syndrome	329
H. Pathophysiology	330
I. Aspirin and Reye's Syndrome	332
J. Animal Models	334
K. Reye's Syndrome in Adults	335
L. Treatment	335
M. Sequelae	336
References	337

CHAPTER 15

Drug Hepatotoxicity in the Elderly

K. KITANI. With 7 Figures	341
A. Introduction	341
B. Clinical Information	341
I. Idiosyncratic Hepatotoxicity: The Swedish Experience	341
II. Dose-Dependent Hepatotoxicity	343

C. Age-Related Alterations in Hepatic Detoxifying Functions:	
Discrepancies Between Human and Animal Data	343
I. Phase I Drug Metabolism	344
II. Phase II Metabolism	346
1. Glucuronidation and Sulfation:	
Acetaminophen Conjugation	346
2. Glutathione S-Transferases	347
III. Oxidant and Antioxidant Variables	350
1. Lipid Peroxidation	351
2. Glutathione	351
3. Antioxidant Enzymes	351
D. Morbidity and Frailty as Major Factors for Lowered Drug	
Clearances in the Elderly: A Possible Role in Hepatotoxicity	353
E. Adverse Drug Reactions in the Liver in Old Animals:	
Mini Review	354
I. Hepatocyte Susceptibility to Chlorpromazine	
and Erythromycin Estolate	355
II. Acetaminophen Hepatotoxicity: An Example	
of Variability of the Results in Studies Using Rodents	355
III. Ethanol Metabolism in the Liver and Its Hepatotoxicity:	
Another Controversy	358
IV. Hepatotoxicities by Other Toxicants	361
F. Conclusions and Suggestions for Future Studies	361
References	362

CHAPTER 16

Effect of Liver Disease on Drug Metabolism and Pharmacokinetics

P.G. WELLING and W.F. POOL. With 6 Figures	367
A. Introduction	367
B. Function and Structure of the Liver	368
C. Types and Severity of Liver Disease	369
I. Changes in Hepatic Function	369
II. Changes in Hepatic Vasculature	369
III. Changes in Renal Function	370
IV. Ascites	370
D. Pharmacodynamic Factors	370
E. Pharmacokinetic Factors	371
I. Linear Pharmacokinetic Models	371
1. One-Compartment Model, Intravenous Dosing	371
2. First-Order Absorption and Elimination	373
3. Repeated Dosing with Linear Pharmacokinetics	374
II. Nonlinear Pharmacokinetic Models	376

III. Impact of Liver Disease	377
1. Distribution Volume	379
2. Elimination Half-Life	379
3. Protein Binding	380
4. Presystemic Clearance	380
F. Markers of Liver Disease Relevant to Drug Metabolism and Pharmacokinetics	381
G. Examples of Effects of Liver Disease on the Pharmacokinetics of Some Drug Therapeutic Classes	382
I. Cardiovascular Agents	383
II. Drugs Acting on the Central Nervous System	384
III. Antimicrobial Agents	385
IV. Other Drugs	386
H. Conclusions	387
References	388

CHAPTER 17

Liver Reactions to Tacrine

T.F. WOOLF, W.F. POOL, R.M. WALKER, and D.K. MONTEITH.

With 2 Figures	395
A. Introduction	395
B. Clinical Experience	395
C. Metabolism of Tacrine in Humans	397
D. Preclinical Toxicology	399
E. Metabolism of Tacrine in Animals	401
F. Cytotoxicity Studies	402
G. In Vitro Metabolism Studies	403
H. Conclusions	405
References	406

CHAPTER 18

Mechanisms of Hypertransaminemia

M. PIRMOHAMED and B.K. PARK. With 7 Figures	411
A. Introduction	411
B. Overview of Liver Transaminase Monitoring	411
I. Significance of the Different Tests Used to Monitor Liver Function	411
II. Spectrum of Drug-Induced Hepatotoxicity and Hypertransaminemia	413

III. Clinical Correlates of Transaminase Measurement	414
1. Sensitivity and Specificity of Hypertransaminemia	414
2. Correlation Between Severity of Hepatic Injury and Degree of Hypertransaminemia	415
3. Clinical Significance of Minor Degrees of Hypertransaminemia	416
C. Classification of the Causes of Hypertransaminemia	419
D. Mechanisms of Acute Hepatic Injury Leading to Hypertransaminemia	419
I. Role of Drug Metabolism	419
II. Evidence for the Formation of Chemically Reactive Metabolites	421
III. Acute Chemical Hepatotoxicity	422
1. Acetaminophen Hepatotoxicity	422
2. Carbon Tetrachloride Hepatotoxicity	424
IV. Acute Idiosyncratic Hepatotoxicity	425
1. Metabolic Idiosyncrasy Causing Hypertransaminemia	425
2. Immune-Mediated Drug-Induced Hypertransaminemia	426
E. Mechanisms of Chronic Hepatic Injury Causing Hypertransaminemia	431
I. Chronic Chemical Hypertransaminemia	431
II. Chronic Idiosyncratic Drug-Induced Hypertransaminemia	432
F. Diagnosis of Drug-Induced Hypertransaminemia	433
I. Distinction Between Drug- and Non-Drug-Induced Etiologies	433
II. Distinction Between Direct and Immune-Mediated Acute Idiosyncratic Toxicity	433
G. Conclusions	434
References	435

CHAPTER 19

Diagnostic Tools and Clinical Pathology

D.C. SNOVER	441
A. General Features and Clinical Evaluation of Drug-Induced Liver Diseases	441
B. General Mechanisms of Drug Reactions	442
I. Toxic Reactions	442
II. Idiosyncratic Reactions	443
III. Tumor Formation	443
IV. Vascular Reactions	444
V. Interactions	445

C. General Biochemical and Histological Types of Drug Reactions . . .	445
I. Hepatocellular Reactions	445
II. Cholestatic Reactions	447
III. Mixed Hepatocellular-Cholestatic	448
IV. Tumors	448
V. Vascular Lesions	448
D. Clinical Evaluation and Diagnosis of Hepatic Drug Reactions	449
I. History	450
II. Laboratory Findings	450
III. Histopathological Findings	451
E. Some Specific Illustrative Drug Reactions	451
I. Unsuspected Acetaminophen Overdose Caused by Consumption of Nyquil	451
II. Suspected Fatal Isoniazid Toxicity Disproven by Autopsy Examination	452
III. Toxicity Due to Health Food ("Hot Stuff")	452
F. Summary of the Clinical Approach to Drug Toxicity	453
References	453

CHAPTER 20

Antimicrobial Drugs

H.J. ZIMMERMAN and K.G. ISHAK. With 7 Figures	457
A. Antibiotics	457
I. Aminoglycosides	457
II. Cephalosporins	457
III. Chloramphenicol	457
IV. Clindamycin	458
V. Colimycin	458
VI. Erythromycin	459
VII. Fusidic Acid	460
VIII. Roxithromycin	460
IX. Tetracyclines	461
X. Troleandomycin	461
XI. Penicillin	462
B. Synthetic Antimicrobials	463
I. Organic Arsenicals	463
II. Quinolones	467
III. Sulfonamides	468
IV. Sulfamethoxazole-Trimethoprim	468
V. Sulfasalazine	468
VI. Sulfones	468
VII. Nitrofurantoin	469
VIII. Furazolidone	469

C. Antituberculous Drugs	469
I. <i>p</i> -Aminosalicylic Acid	469
II. Isoniazid	470
III. Rifampin	470
D. Antifungal Agents	471
I. Griseofulvin	471
II. Ketoconazole	471
III. Other Imidazoles	471
IV. Flucytosine	471
E. Antiviral Agents	472
F. Antiprotozoal Agents	472
I. Anthelmintics	472
References	473

CHAPTER 21

Hepatotoxicity of Cardiovascular Drugs

R.G. CAMERON, F.A. DE LA IGLESIA, and G. FEUER. With 9 Figures	477
A. Introduction	477
B. α -Methyldopa	478
I. Hepatitis	479
II. Fatty Change	481
III. Hepatic Necrosis	482
IV. Cholestasis	482
V. Cirrhosis	483
C. Amiodarone	483
I. Alcoholic-Type Hepatitis	484
II. Phospholipid Fatty Liver	487
III. Reye's Syndrome-Like Disease	488
D. Aprindine	488
I. Hepatitis	488
E. Hydralazine and Dihydralazine	489
I. Hepatitis	490
F. Papaverine	491
I. Hepatitis	492
G. Procainamide	492
I. Hepatitis	492
II. Cholestasis	493
H. Quinidine	493
I. Hepatitis	494
II. Granulomatous Hepatitis	494
I. Lipid-Regulating Agents	495
I. Classes of Lipid-Regulating Agents	495
II. Hyperlipoproteinemia and Liver Structure	496
III. Nicotinic Acid	498

IV. Fibrates	498
V. Statins	500
J. Miscellaneous Cardiovascular Drugs	501
K. Modulation of Hepatotoxicity	502
L. Conclusions	502
References	504

CHAPTER 22

Analgesic Hepatopathy

M.J. ZUCKERMAN and S. ANURAS	515
A. Introduction	515
B. Acetaminophen	515
I. Epidemiology	515
1. Incidence of Hepatotoxicity	515
2. Hepatotoxicity in Alcoholics	516
3. Hepatotoxicity in Therapeutic Settings	517
II. Pathogenesis	518
1. Hepatotoxic Dose and Blood Level	518
2. Mechanism	518
3. Factors Influencing Hepatotoxicity	519
III. Clinical Manifestations and Laboratory Findings	519
1. Clinical Course	519
2. Pathology	520
3. Prognosis	521
IV. Treatment	522
1. General Management	522
2. Specific Therapy	523
3. Fulminant Hepatic Failure	524
V. Prevention	525
C. Nonsteroidal Antiinflammatory Drugs	526
I. Epidemiology	526
II. Pathogenesis	529
III. Clinical Manifestations and Laboratory Findings	531
1. General Observations	531
2. Specific NSAIDs	532
IV. Treatment	534
V. Prevention	535
D. Narcotic Analgesics	536
References	537

CHAPTER 23

Steroids and Other Hormones

H.J. ZIMMERMAN and K.G. ISHAK. With 7 Figures	543
---	-----

A. Gonadal Steroids and Their Derivatives	543
B. Anabolic Steroids	543
I. Cholestasis	544
1. Structural Characteristics of Ictero-genic Steroids	544
2. Incidence	544
3. Clinical Features	545
4. Biochemical Features	546
5. Histopathology	546
6. Prognosis	546
7. Mechanism	547
II. Peliosis Hepatis	548
III. Neoplasms	549
1. Nodular Regenerative Hyperplasia	549
2. Hepatocellular Adenoma	549
3. Hepatic Carcinoma	550
4. Other Neoplasms	550
C. Female Sex Hormones and the Contraceptive Steroids	551
I. Estrogenic Hormones and Related Drugs	551
II. Progestational Steroids	552
III. Adverse Effects of Contraceptive Steroids on the Liver . . .	553
IV. Syndrome of Contraceptive Steroid Jaundice	554
1. Clinical Features	554
2. Biochemical Features	554
3. Histologic Characteristics	554
4. Prognosis	554
5. Susceptibility	554
V. Tumors Associated with Oral Contraceptives	555
1. Hepatocellular Adenoma	555
2. Focal Nodular Hyperplasia	558
3. Hepatocellular Carcinoma	558
VI. Vascular Lesions	560
1. Effect on Hemangiomas and Related Lesions	560
2. Sinusoidal Dilatation	560
3. Peliosis Hepatis	560
4. Hepatic Vein Thrombosis	561
5. Rupture of the Liver	562
6. Other Vascular Changes	563
VII. Disturbed Porphyrin Metabolism	563
VIII. Mechanisms of Injury by Contraceptive Steroids	563
IX. Cholelithiasis	564
D. Drugs Related to Sex Hormones	565
I. Antiestrogens	565
1. Clomiphene	565
2. Cyclofenil	565
3. Tamoxifen	565

II. Antihypophysial Drugs	565
1. Danazol	565
2. Octreotide	566
E. Glucocorticoids	566
F. Oral Hypoglycemic Agents	566
I. Sulfonylureas	566
II. Clinical Syndrome	567
III. Prognosis	568
IV. Biguanide	569
V. Other Oral Hypoglycemic Agents	569
G. Antithyroid Drugs	569
I. Form of Injury	570
II. Clinical Features	570
III. Prognosis	570
IV. Mechanism	571
V. Comment	571
References	571

CHAPTER 24

Hepatotoxicity of Immunomodulating Agents

R.J. FINGEROTE and G.A. LEVY	581
A. Introduction	581
B. Immunostimulatory Agents	582
I. Classification	582
1. Immune-System-Derived Biologicals	583
2. Immunostimulatory Pharmaceutical Agents	583
II. Hepatotoxicity of Specific Immunostimulatory Agents	583
1. Interleukin-2	583
2. Interferons	585
C. Immunosuppressive Agents	588
I. Classification	588
1. Antilymphocyte Products	589
2. Immunophilin-Binding Agents	589
3. Cytotoxic Agents	589
4. Sterols	590
5. Immunosuppressive Antibiotics	590
6. Arachidonic Acid Metabolites	590
II. Hepatotoxic Effects of Specific Immunosuppressive Agents	591
1. Methotrexate	591
2. Corticosteroids	594
3. Azathioprine	595

4. Cyclosporine	598
5. FK-506	601
D. Conclusion	602
References	602

CHAPTER 25

Alcohol-Induced Liver Injury

Y. ISRAEL and E. RUBIN	611
A. Epidemiology	611
B. Liver Dysfunction in Alcoholic Liver Disease	612
I. Hemodynamic Alterations	612
II. Liver Failure	613
C. Alcoholic Liver Injury: Morphological Studies	615
I. Hepatocytes	615
II. Inflammation	616
III. Collagen Deposition	616
IV. Nonparenchymal Cells (EM Studies)	616
1. Ito Cells	616
2. Endothelial Cells	616
3. Kupffer Cells	616
D. Clustering	617
I. Fatty Liver	617
II. Alcoholic Hepatitis	617
III. Alcoholic Cirrhosis	617
E. Pathogenesis of Alcohol-Induced Liver Injury	617
I. Liquid Diet Model	617
II. Cytochrome P450 2E1	618
III. Acetaldehyde Adducts	619
IV. Hepatocyte Ballooning and Hepatomegaly	620
V. Hepatic Oxygen Consumption	621
VI. Liver Hypoxia	622
VII. Intra gastric Infusion Model	623
VIII. Modulation of Alcohol-Induced Liver Injury	624
IX. Glutathione	626
X. Micropig Model of Alcoholic Liver Injury	627
XI. Baboon Model of Alcoholic Liver Injury	627
References	628

CHAPTER 26

Antiepileptic Drugs

H.J. ZIMMERMAN and K.G. ISHAK. With 10 Figures	637
--	-----

A. Phenytoin	637
I. Type of Hepatic Injury	637
II. Clinical Manifestations	638
III. Biochemical Features	640
IV. Histopathology	640
V. Prognosis	641
VI. Mechanism	643
VII. Other Hydantoins	645
1. Mephenytoin	645
2. Acetylurea Derivatives	645
3. Oxazolidinediones	646
4. Barbiturates and Primidone	646
B. Carbamazepine	646
I. Susceptibility	646
II. Clinical Features	647
III. Biochemical Features	647
IV. Histopathology	648
V. Prognosis	648
VI. Mechanism	648
C. Valproic Acid	649
I. Incidence of Injury	649
II. Susceptibility	650
III. Clinical Features	650
IV. Biochemical Features	652
V. Histopathology	652
VI. Prognosis	654
VII. Mechanism of Injury	654
VIII. Prevention	657
References	657
 Subject Index	 663